1484327-92-5

Basic information

• Product Name: tert-butyl 2-(4-Methylpiperazin-1-yl)ethylcarbaMate
• Synonyms: tert-butyl 2-(4-Methylpiperazin-1-yl)ethylcarbaMate
• CAS NO: 1484327-92-5
• Molecular Formula: C12H25N3O2
• Molecular Weight: 243.3458
• EINECS: -0
• Mol File: 1484327-92-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: tert-butyl 2-(4-Methylpiperazin-1-yl)ethylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-(4-Methylpiperazin-1-yl)ethylcarbaMate(1484327-92-5)
• EPA Substance Registry System: tert-butyl 2-(4-Methylpiperazin-1-yl)ethylcarbaMate(1484327-92-5)

Safety Data

• Hazardous Substances Data: 1484327-92-5(Hazardous Substances Data)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 96628-67-0 2-(tert-butoxycarbonylamino)ethyl methanesulfonate 
• 4530-20-5 BOC-glycine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 53788-49-1 tert-butyl 4-methylpiperazine-1-carboxylate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 934-98-5 2-(4-methylpiperazin-1-yl)ethylamine 

Relevant articles and documents

Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8H)-one Derivatives as Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

In recent years, the adenosine A2A receptor (A2AR) has shown exciting progress in the development of immunotherapies for the treatment of cancer. Herein, a 2-amino-7,9-dihydro-8H-purin-8-one compound (1) was identified as an A2AR antagonist hit through in-house library screening. Extensive structure-activity relationship (SAR) studies led to the discovery of 2-aminopteridin-7(8H)-one derivatives, which showed high potencies on A2AR in the cAMP assay. Compound 57 stood out with an IC50 value of 8.3 ± 0.4 nM against A2AR at the 5′-N-ethylcarboxamidoadenosine (NECA) level of 40 nM. The antagonistic effect of 57 was sustained even at a higher NECA concentration of 1 μM, which mimicked the adenosine level in the tumor microenvironment (TME). Importantly, 57 enhanced T cell activation in both the IL-2 production assay and the cancer-cell-killing model, thus demonstrating its potential as a lead for developing novel A2AR antagonists in cancer immunotherapy.

Synthesis and evaluation of chirally defined side chain variants of 7-chloro-4-aminoquinoline to overcome drug resistance in malaria chemotherapy

A novel 4-aminoquinoline derivative [(S)-7-chloro-N-(4-methyl-1-(4-methyl-piperazin-1-yl)pentan-2-yl)-quinolin-4-amine triphosphate] exhibiting curative activity against chloroquine-resistant malaria parasites has been identified for preclinical development as a blood schizonticidal agent. The lead molecule selected after detailed structure-activity relationship (SAR) studies has good solid-state properties and promising activity against in vitro and in vivo experimental malaria models. The in vitro absorption, distribution, metabolism, and excretion (ADME) parameters indicate a favorable drug-like profile.